Physician profile
Robert Bruno
NPI 1740220730
$9,204.58
in general payments reported to CMS, 2019-2025
39 companies · $1,757 in 2025
The $1,757 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,154 · 2020: $396 · 2021: $1,582 · 2022: $1,489 · 2023: $1,272 · 2024: $1,554 · 2025: $1,757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,537 · Education: $45.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,537.40 |
| Education | $45.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,997.62 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $602.42 | 2019-2025 | Jynarque, Voyxact |
| Novo Nordisk INC | $570.38 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $566.98 | 2019-2025 | Benlysta, Arexvy, Jesduvroq |
| Amgen INC. | $459.18 | 2022-2025 | Tavneos, Krystexxa, Aranesp |
| Boehringer Ingelheim Pharmaceuticals, INC. | $419.72 | 2021-2025 | Jardiance |
| Abbvie INC. | $373.96 | 2021-2022 | |
| Bard Peripheral Vascular, INC. | $339.48 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $280.28 | 2021-2025 | Lupkynis |
| Fresenius USA Marketing, INC. | $271.05 | 2019-2025 | Velphoro, Velphoro |
| Amarin Pharma, INC. | $249.68 | 2019-2020 | |
| Vifor Pharma, INC. | $239.70 | 2019-2025 | Veltassa |
| E.R. Squibb & Sons, L.L.C. | $207.81 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $206.24 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $205.89 | 2019-2025 | Rayaldee |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bruno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.